Azura Crescencia
Mesenchymal stem cell (MSC) therapy holds promise for treating various diseases due to their immunomodulatory and regenerative properties. However, its clinical translation faces significant regulatory challenges. This abstract explores the current landscape of clinical trials involving MSC therapy, highlighting regulatory hurdles such as standardization of protocols, safety concerns and ethical considerations. Understanding these challenges is crucial for advancing MSC therapy from experimental studies to widespread clinical application, ensuring both efficacy and patient safety.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 